ES2195071T3 - Compuestos sustituidos con sulfonamida como bloqueadores del canal de k. - Google Patents

Compuestos sustituidos con sulfonamida como bloqueadores del canal de k.

Info

Publication number
ES2195071T3
ES2195071T3 ES97121437T ES97121437T ES2195071T3 ES 2195071 T3 ES2195071 T3 ES 2195071T3 ES 97121437 T ES97121437 T ES 97121437T ES 97121437 T ES97121437 T ES 97121437T ES 2195071 T3 ES2195071 T3 ES 2195071T3
Authority
ES
Spain
Prior art keywords
blockers
sulfonamide
channel
substituted compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97121437T
Other languages
English (en)
Inventor
Joachim Brendel
Hans Jochen Lang
Uwe Gerlach
Klaus Weidmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996152213 external-priority patent/DE19652213A1/de
Priority claimed from DE1997130326 external-priority patent/DE19730326A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2195071T3 publication Critical patent/ES2195071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA I CON LOS SIGNIFICADOS CITADOS EN LAS REIVINDICACIONES SON SUSTANCIAS EXTRAORDINARIAMENTE ACTIVAS PARA LA PRODUCCION DE MEDICAMENTOS PARA LA PROFILAXIS Y PARA LA TERAPIA DE ENFERMEDADES CARDIACO-CIRCULATORIAS, ESPECIALMENTE ARRITMIAS, PARA EL TRATAMIENTO DE LA ULCERA DE ESTOMAGO Y DE LA ZONA INTESTINAL O PARA EL TRATAMIENTO DE ENFERMEDADES DIARREICAS.
ES97121437T 1996-12-16 1997-12-05 Compuestos sustituidos con sulfonamida como bloqueadores del canal de k. Expired - Lifetime ES2195071T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996152213 DE19652213A1 (de) 1996-12-16 1996-12-16 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE1997130326 DE19730326A1 (de) 1997-07-15 1997-07-15 Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ES2195071T3 true ES2195071T3 (es) 2003-12-01

Family

ID=26032247

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97121437T Expired - Lifetime ES2195071T3 (es) 1996-12-16 1997-12-05 Compuestos sustituidos con sulfonamida como bloqueadores del canal de k.

Country Status (24)

Country Link
US (1) US5856338A (es)
EP (1) EP0847996B1 (es)
JP (1) JP4317601B2 (es)
KR (1) KR19980064151A (es)
CN (1) CN1185435A (es)
AT (1) ATE234821T1 (es)
AU (1) AU725699B2 (es)
BR (1) BR9706142A (es)
CA (1) CA2224885A1 (es)
CZ (1) CZ403997A3 (es)
DE (1) DE59709560D1 (es)
DK (1) DK0847996T3 (es)
ES (1) ES2195071T3 (es)
HR (1) HRP970684A2 (es)
HU (1) HUP9702475A3 (es)
ID (1) ID19152A (es)
IL (1) IL122576A0 (es)
NO (1) NO975887L (es)
NZ (1) NZ329200A (es)
PL (1) PL323809A1 (es)
PT (1) PT847996E (es)
SI (1) SI0847996T1 (es)
SK (1) SK171797A3 (es)
TR (1) TR199701605A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711220D0 (en) * 1997-05-30 1997-07-23 Isis Innovation Antiarrhythmic agents
AU5542101A (en) 2000-04-14 2001-10-30 Univ Vanderbilt Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CN113402476B (zh) * 2021-06-21 2022-04-19 广东湛江海洋医药研究院 一种亚胺噁嗪衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737195A1 (de) * 1987-11-03 1989-05-18 Bayer Ag Chromanderivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB8808069D0 (en) * 1988-04-07 1988-05-11 Fujisawa Pharmaceutical Co Benzopyran derivatives & processes for preparation thereof
FR2639349B1 (fr) * 1988-11-23 1991-02-22 Sanofi Sa Nouveaux derives du chromane actifs sur le systeme nerveux central, leur procede de preparation et les compositions pharmaceutiques en contenant
US5104890A (en) * 1989-03-28 1992-04-14 Fujisawa Pharmaceutical Company, Ltd. Benzopyran derivatives and processes for preparation thereof
ES2145129T3 (es) * 1992-08-17 2000-07-01 Chugai Pharmaceutical Co Ltd Derivados de benzopirano y benzoxazina.
PT807629E (pt) * 1996-05-15 2004-07-30 Aventis Pharma Gmbh Cromanos substituidos por sulfonamidas processo para a sua preparacao a sua utilizacao como medicamentos ou agentes de diagnostico bem como medicamentos que os contem

Also Published As

Publication number Publication date
MX9710126A (es) 1998-07-31
HRP970684A2 (en) 1998-10-31
AU725699B2 (en) 2000-10-19
SI0847996T1 (en) 2003-08-31
CA2224885A1 (en) 1998-06-16
SK171797A3 (en) 1998-07-08
DK0847996T3 (da) 2003-06-30
HUP9702475A2 (hu) 1999-06-28
HUP9702475A3 (en) 2000-01-28
EP0847996B1 (de) 2003-03-19
ID19152A (id) 1998-06-18
NO975887D0 (no) 1997-12-15
IL122576A0 (en) 1998-06-15
TR199701605A2 (xx) 1998-07-21
ATE234821T1 (de) 2003-04-15
BR9706142A (pt) 1999-05-18
PT847996E (pt) 2003-07-31
DE59709560D1 (de) 2003-04-24
PL323809A1 (en) 1998-06-22
US5856338A (en) 1999-01-05
CN1185435A (zh) 1998-06-24
CZ403997A3 (cs) 1998-07-15
JPH10182610A (ja) 1998-07-07
NZ329200A (en) 1999-05-28
AU4837397A (en) 1998-06-18
JP4317601B2 (ja) 2009-08-19
NO975887L (no) 1998-06-17
EP0847996A1 (de) 1998-06-17
HU9702475D0 (en) 1998-03-02
KR19980064151A (ko) 1998-10-07

Similar Documents

Publication Publication Date Title
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ES2191192T3 (es) Tienopirimidinas.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
UY26186A1 (es) Inhibidores de metaloproteasas
ES2191286T3 (es) Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias.
ES2191511B1 (es) Derivados conjugados de eritropoyetina.
AR029941A1 (es) Compuestos utiles para elevar el nivel plasmatico de la hormona del crecimiento y las composiciones farmaceuticas que las contienen
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
ES2093694T3 (es) Nuevos derivados de dihidro-isoquinoleina.
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
ES2150113T3 (es) Derivados de pirazol y procedimientos para la preparacion de los mismos.
ES2170938T3 (es) Utilizacion del factor neurotrofico derivado de celulas gliales (gdnf) para el tratamiento de las deficiencias auditivas.
HN1998000035A (es) Nuevos derivados del acido hexanoico
AR008991A1 (es) Compuestos de dimetil-(3-aril-but-3-enil)-amina, procedimientos para su preparacion y aplicacion de los mismos
DE3774918D1 (de) Cancerostatisches mittel.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PA8467301A1 (es) Nuevos derivados del acido dihidroxihexanoico
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
ES2195071T3 (es) Compuestos sustituidos con sulfonamida como bloqueadores del canal de k.
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
ES2090875T3 (es) Tratamiento de enfermedades inflamatorias del intestino.
ES2032317T3 (es) Derivados de quinazolina tetraciclicos, obtencion y empleo.